Geo Vax Appoints Dr. Marc Pipas As Executive Medical Director, Oncology

Jan 08, 2024•over 1 year ago

Position

Executive Medical Director

Company

GeoVax

Marc Pipas

SmyrnaBiotechnology

Description

GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company’s Executive Medical Director, Oncology.

Company Information

Company

GeoVax

Location

Smyrna, Georgia, United States

About

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months